Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
AIKO
Portland, Maine, United Statesaikobiotech.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
AIKO Biotechnology developed novel small molecule opioid antagonists and modulators designed to treat pain and mitigate the side effects of prescription opioids. Their lead compound, AIKO-150, completed two Phase 1 clinical trials demonstrating high potency in blocking opioid-induced gastrointestinal effects without interfering with analgesia. The company also worked on analogs such as naltrexol and naltrexamine. As of May 2025, the company is dissolved and its pipeline discontinued.
- Therapeutic areas
- PsychiatryGastroenterologyNeurology
- Modalities
- Small molecule
- Industry
- Biotech
02
Partnerships
None reported in public sources.
Beyond the preview
Go deeper on AIKO.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AIKO.